Advertisement

Topics

Potential Blockbuster Drugs Expected to Hit Dermatology Space

06:10 EDT 5 Jul 2017 | PharmPro

Dermatology space to benefit most from five potential blockbusters by 2023, says GBI Research. Cosentyx, Otezla, Eucrisa and Taltz were approved for psoriasis. Dupixent is the first and only biologic to be approved for atopic dermatitis.
Contributed Author: 
GBI Research
Topics: 

Original Article: Potential Blockbuster Drugs Expected to Hit Dermatology Space

NEXT ARTICLE

More From BioPortfolio on "Potential Blockbuster Drugs Expected to Hit Dermatology Space"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Dermatology
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...

Psoriasis
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...